CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Inclusion Criteria:

Histologically or cytologically proven SCLC that has relapsed or been refractory from at least one line of chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of =< 3
Expected survival > 1 month
No acute toxicities from previous treatment higher than grade 1 at the start of treatment with CPI-613
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation
Men must practice effective contraceptive methods during the study, unless documentation of infertility exists
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL)
Bilirubin =< 1.5 x UNL
Serum creatinine =< 1.5 mg/dL or 133 µmol/L
Albumin > 2.0 g/dL or > 20 g/L
Mentally competent, ability to understand and willingness to sign an Institutional Review Board (IRB)-approved written informed consent form
Have access via central line (e.g., portacath)-double lumen due to CPI-613 administration requirements

Exclusion Criteria:

Patients receiving any other standard or investigational treatment for their cancer, or any investigational agent for any non-cancer indication within the past 2 weeks prior to initiation of CPI-613 treatment
Serious medical illness that would potentially increase patients' risk for toxicity
Any active uncontrolled bleeding or bleeding diathesis
Pregnant women, women of child-bearing potential not using reliable means of contraception, or lactating women
Men unwilling to practice contraceptive methods during the study period
Life expectancy less than 1 month
Treatment with any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613
Patients with untreated central nervous system (CNS) or epidural tumor
Any condition or abnormality which may, in the opinion of the investigator, compromise his or her safety
Unwilling or unable to follow protocol requirements
Active heart disease including myocardial infarction within previous 6 months, symptomatic coronary artery disease, arrhythmias not controlled with medication, or symptomatic congestive heart failure
Evidence of active infection or serious infection (e.g., septic shock with multi-organ dysfunction) within the past month
Patients with known human immunodeficiency virus (HIV) infection
Requirement for immediate palliative treatment of any kind including surgery